Tagged with BI

China A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled research deal with CSPC Pharmaceuticals, and the FDA blocks clinical trials that export American’s cells to China. Sciwind’s GLP‑1 data…

Switzerland Currently supplying high-quality medicines to approximately 1 billion patients around the world annually, few pharmaceutical companies straddle both scale and innovation as deliberately as Viatris. In Switzerland – a market perceived as small in scale, yet rich in complexity – the company is redefining its role, identifying where it can…

Switzerland Stefan Schmidt traces a dynamic career from early biotech ventures in Germany to senior leadership roles at AstraZeneca, Lonza, and now CEO of evitria, a specialised Swiss CRO focused on complex antibody development. Evitria is expanding its technology and global reach to become a key partner in bispecific and engineered…

Switzerland Luc Henry, co-founder and CEO of Limula, speaks about the challenges and opportunities in the field of cell and gene therapy. A chemist by training, Henry’s path from molecular sciences to cancer immunology and ultimately to entrepreneurship reveals how interdisciplinary thinking can catalyse bold innovation. In this conversation, Henry explains…

Switzerland Thomas Bohn has led the Greater Geneva Bern area (GGBa) investment agency for over a decade, shaping Switzerland’s strategy to attract global life sciences firms. He focuses on quality over quantity, targeting high-potential biotech, pharma, and medtech companies and supporting their European growth through sustainable partnerships. Switzerland’s life sciences heritage…

Denmark Curiosity has been the driving force behind Montse Jansà’s journey, a curiosity not only for science, but for the people, processes, and decisions that bring innovation to life. From a foundation in biology and clinical research to leadership roles across Europe, she has consistently sought opportunities to create meaningful impact.…

China Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with the speed of a startup and the reach of an MNC. As Founder, CEO, and Chairman of Duality Biotherapeutics, Zhu…

Germany Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and China is at the heart of its strategy. Using vaccine proceeds to tap China’s booming life sciences ecosystem, BioNTech has…

Denmark Peter Jorgensen, Director of the Danish Generic and Biosimilar Medicines Industry Association, discusses Denmark’s robust framework for generics and biosimilars, offering insight into a system that has delivered high penetration, cost savings, and broad public trust. From legal structures and patient attitudes to incentives and hospital adoption, Jorgensen outlines why…

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

Germany A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut with SpringWorks Therapeutics; the bispecific antibody alliance between BMS and BioNTech, and Sartorius’ acquisition of microtissue firm MatTek.   Bayer…